MedWatch

Bioporto secures patent in China

The Danish biotech company BioPorto has been issued a cut-off patent in China for a kidney test. The product is now patented in Europe and ten additional countries.

Foto: Bioporto/PR

A cut-off patent  for BioPorto’s kidney test NGAL means that crucial IP rights for the product has now been secured in China, the company writes in a stock market release.

BioPorto now has a cut-off patent for the diagnostic kidney marker NGAL in China, India, Japan, New Zealand, Singapore, Hong Kong, South Africa, South Korea, Australia, Israel, and all of Europe. The company’s applications for cut-off patents in the US and Canada are still under review.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier